Telomerase as a therapeutic target for malignant gliomas

被引:64
作者
Komata, T
Kanzawa, T
Kondo, Y
Kondo, S
机构
[1] Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10029 USA
[2] Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA
关键词
telomerase; telomerase RNA; telomerase reverse transcriptase; apoptosis; glioma;
D O I
10.1038/sj.onc.1205072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Telomerase, a ribonucleoprotein enzyme, is considered as a potential target of cancer therapy because of its preferential expression in tumors. In particular, malignant gliomas are one of the best candidates for telomerase-targeted therapy. It is because malignant gliomas are predominantly telomerase-positive, while normal brain tissues do not express telomerase. In theory, there are two telomerase-associated therapeutic approaches for telomerase-positive tumors. One approach is the anti-telomerase cancer therapy to directly inhibit telomerase activity, resulting in apoptotic cell death or growth arrest. Two major components of the telomerase holoenzyme complex, the RNA template (hTER) and catalytic subunit (reverse transcriptase, hTERT) are well considered as therapeutic targets. The other approach is the telomerase-specific cancer therapy by targeting telomerase-expressing tumor cells as a means to directly kill the cells. Strategies using the transfer of therapeutic gene under the hTERT promoter system as well as immunotherapy directed against telomerase-positive cells are generally included. These telomerase-associated therapies are very promising for the treatment of malignant gliomas.
引用
收藏
页码:656 / 663
页数:8
相关论文
共 86 条
  • [1] Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells
    Abdul-Ghani, R
    Ohana, P
    Matouk, I
    Ayesh, S
    Ayesh, B
    Laster, M
    Bibi, O
    Giladi, H
    Molnar-Kimber, K
    Sughayer, MA
    de Groot, N
    Hochberg, A
    [J]. MOLECULAR THERAPY, 2000, 2 (06) : 539 - 544
  • [2] Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
    Agrawal, S
    Jiang, ZW
    Zhao, QY
    Shaw, D
    Cai, QY
    Roskey, A
    Channavajjala, L
    Saxinger, C
    Zhang, RW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) : 2620 - 2625
  • [3] Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes
    Arai, J
    Yasukawa, M
    Ohminami, H
    Kakimoto, M
    Hasegawa, A
    Fujita, S
    [J]. BLOOD, 2001, 97 (09) : 2903 - 2907
  • [4] A NUCLEIC-ACID TRIPLE-HELIX FORMED BY A PEPTIDE NUCLEIC-ACID DNA COMPLEX
    BETTS, L
    JOSEY, JA
    VEAL, JM
    JORDAN, SR
    [J]. SCIENCE, 1995, 270 (5243) : 1838 - 1841
  • [5] STRUCTURE AND FUNCTION OF TELOMERES
    BLACKBURN, EH
    [J]. NATURE, 1991, 350 (6319) : 569 - 573
  • [6] TELOMERASE ACTIVITY IN NORMAL AND MALIGNANT HEMATOPOIETIC-CELLS
    BROCCOLI, D
    YOUNG, JW
    DELANGE, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (20) : 9082 - 9086
  • [7] BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO
  • [8] 2-2
  • [9] NONENZYMATIC CLEAVAGE AND LIGATION OF RNAS COMPLEMENTARY TO A PLANT-VIRUS SATELLITE RNA
    BUZAYAN, JM
    GERLACH, WL
    BRUENING, G
    [J]. NATURE, 1986, 323 (6086) : 349 - 353
  • [10] Carroll T, 1999, J PATHOL, V188, P395